• $25
  • $50
  • $100
  • other
  • use Paypal

CALLING ALL COUNTERPUNCHERS! CounterPunch’s website is one of the last common spaces on the Internet. We are supported almost entirely by the subscribers to the print edition of our magazine and by one-out-of-every-1000 readers of the site. We aren’t on the receiving end of six-figure grants from big foundations. George Soros doesn’t have us on retainer. We don’t sell tickets on cruise liners to the “new” Cuba. We don’t clog our site with deceptive corporate ads or click bait. Unlike many other indy media sites, we don’t shake you down for money every month … or even every quarter. We ask only once a year. But when we ask, we mean it. So over the next few weeks we are requesting your financial support. Keep CounterPunch free, fierce and independent by donating today by credit card through our secure online server, via PayPal or by calling 1(800) 840-3683. Note: This annoying box will disappear once we reach our fund drive goal. Thank you for your support!


Selling One Pill to Treat Side Effects of Another Pill


Nearly one in four US women is on antidepressants. The drugs, like Prozac, Paxil and Zoloft, may be happy pills but they are not happy-in-the-bedroom pills. Both older and newer antidepressants cause severe sexual dysfunction like diminished libido and anorgasmia, the inability to achieve orgasm, even with adequate stimulation.

Antidepressant sexual dysfunction is so common, it is used as a sales pitch by the drug manufacturers. “Wellbutrin X works for my depression with a low risk of weight gain and sexual side effects,” say glossy magazine ads showing young men whose sexuality is intact thanks to a better antidepressant. “Can your medicine do all that?” One study found 96 percent patients on a particular antidepressant developed anorgasmia. Who likes those statistics?

Now, marketers of two new sex drugs for women are acknowledging how many women are actually on antidepressants. A Dutch company developing the female libido drugs, Lybrido and Lybridos (which are not yet FDA approved or available) believes the drugs may help the antidepressant-related sexual problems, according to an article in the New York Times magazine. Lybrido contains two possible libido enhancers for women, testosterone and sildenafil, the active ingredient in Viagra. But Lybridos contains testosterone and the antidepressant buspirone, a drug already on the market and known to reverse the negative sexual side effects of antidepressants in some cases by modifying changed levels of the neurotransmitter serotonin that cause the sexual dysfunction.

Buspirone is similar to a “female Viagra” drug that almost reached the market a few years ago. Flibanserin, made by the German company Boehringer Ingelheim, was intended to treat “hypoactive sexual desire disorder” in women but rejected by the FDA. Flibanserin was similar to the antidepressant Serzone which is linked to hyper sexual arousal and the abnormal and painful erectile state known as priapism. Serzone has been withdrawn from markets.

Like Viagra (which had been intended to be an angina drug until its erectile effects appeared) flibanserin, the drug rejected three years ago, was groomed to be an antidepressant drug until its effect on female sexual desire surfaced. Some trial participants did not want to surrender their unused pills at the end of the study. But, despite medical and media excitement about flibanserin and pleas from Big Pharma, Wall Street, husbands, boyfriends and women, the FDA rejected flibanserin in 2010–not for its side effects like dizziness, nausea and sleepiness but because it didn’t seem to work.

Thanks to Big Pharma marketing, Americans increasingly seek a quick fix for “depression,” “sexual dysfunction” and other lifestyle problems. Before direct to consumer marketing of antidepressants, people did not expect to be deliriously happy for no reason or term their problems with marriages and relationships, jobs, health and money, “depression.” Medicalizing lifestyle problems is a cash cow for Big Pharma because advertising works.

Of course, there is no assurance that Lybrido and Lybridos will be approved by the FDA or gain acceptance among doctors and women. But if they do, Big Pharma’s audacious business model of selling one expensive pill to treat side effects of another expensive pill will surely please Wall Street.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).


Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

October 13, 2015
Dave Lindorff
US Dispatched a Murderous AC-130 Airborne Gunship to Attack a Hospital
Steve Martinot
The Politics of Prisons and Prisoners
Heidi Morrison
A Portrait of an Immigrant Named Millie, Drawn From Her Funeral
Andre Vltchek
Horrid Carcass of Indonesia – 50 Years After the Coup
Jeremy Malcolm
All Rights Reserved: Now We Know the Final TTP is Everything We Feared
Omar Kassem
Do You Want to See Turkey Falling Apart as Well?
Paul Craig Roberts
Recognizing Neocon Failure: Has Obama Finally Come to His Senses?
Theodoros Papadopoulos
The EU Has Lost the Plot in Ukraine
Roger Annis
Ukraine Threatened by Government Negligence Over Polio
Matthew Stanton
The Vapid Vote
Mel Gurtov
Manipulating Reality: Facebook is Listening to You
Louisa Willcox
Tracking the Grizzly’s Number One Killer
Binoy Kampmark
Assange and the Village Gossipers
Robert Koehler
Why Bombing a Hospital Is a War Crime
Jon Flanders
Railroad Workers Fight Proposed Job Consolidation
Mark Hand
Passion and Pain: Photographer Trains Human Trafficking Survivors
October 12, 2015
Ralph Nader
Imperial Failure: Lessons From Afghanistan and Iraq
Ishmael Reed
Want a Renewal? Rid Your City of Blacks
Thomas S. Harrington
US Caught Faking It in Syria
Victor Grossman
Scenes From a Wonderful Parade Against the TPP
Luciana Bohne
Where Are You When We Need You, Jean-Paul Sartre?
Kevin Zeese - Margaret Flowers
The US Way of War: From Columbus to Kunduz
Paul Craig Roberts
A Decisive Shift in the Balance of Power
Justus Links
Turkey’s Tiananmen in Context
Ray McGovern
Faux Neutrality: How CNN Shapes Political Debate
William Manson
Things R Us: How Venture Capitalists Feed the Fetishism of Technology
Norman Pollack
The “Apologies”: A Note On Usage
Steve Horn
Cops Called on Reporter Who Asked About Climate at Oil & Gas Convention
Javan Briggs
The Browning of California: the Water is Ours!
Dave Randle
The BBC and the Licence Fee
Andrew Stewart
Elvis Has Left the Building: a Reply to Slavoj Žižek
Nicolás Cabrera
Resisting Columbus: the Movement to Change October 12th Holiday is Rooted in History
Weekend Edition
October 9-11, 2015
David Price – Roberto J. González
The Use and Abuse of Culture (and Children): The Human Terrain System’s Rationalization of Pedophilia in Afghanistan
Mike Whitney
Putin’s “Endgame” in Syria
Jason Hribal
The Tilikum Effect and the Downfall of SeaWorld
Gary Leupp
The Six Most Disastrous Interventions of the 21st Century
Andrew Levine
In Syria, Obama is Playing a Losing Game
Louis Proyect
The End of Academic Freedom in America: the Case of Steven Salaita
Rob Urie
Democrats, Neoliberalism and the TPP
Ismael Hossein-Zadeh
The Bully Recalibrates: U.S. Signals Policy Shift in Syria
Brian Cloughley
Hospital Slaughter and the US/NATO Propaganda Machine
Paul Street
Hope in Abandonment: Cuba, Detroit, and Earth-Scientific Socialism
John Walsh
For Vietnam: Artemisinin From China, Agent Orange From America
Hadi Kobaysi
How The US Uses (Takfiri) Extremists
John Wight
No Moral High Ground for the West on Syria